… Pancreatic cancer is the fourth leading cause of cancer-… Conventional treatments for pancreatic
cancer are scarcely … Suicide or prodrug-converting cancer gene therapy may represent a …

… patients with pancreatic cancer is extremely … selection in trials of interventions are needed
to improve the yield from research efforts. Pancreatic cancer remains a major cause of cancer …

… that specific targeted therapies will be effective in only a subset of patients, and, as such,
a personalized approach will be required to select the right drug for each individual patient. …

… Compared with HDACs, the contribution of HATs to pancreatic cancer formation and
progression is multifaceted and highly dependent on the cellular context and the selection of …

… selected genetic markers, and advances in nanomedicine for early diagnosis of pancreatic
cancer… with a family history of pancreatic cancer, chronic pancreatitis, precancerous lesions, …

… Gemcitabine, an established standard therapy for advanced pancreatic cancer, was
selected as the reference comparator in the Bayesian network meta-analysis because it has …

… Previously gemcitabine has been dosed at 100 mg/kg publications for pancreatic cancer,
in … at 15 mg/kg for IV injections in pancreatic cancer, Citation42 and when we performed IP …

… pancreatic cancer prognosis. Furthermore, there have been no reports of the selection of
pancreatic cancer … , treatment selection and laboratory test data for pancreatic cancer to guide …

… In this scenario the evaluation of targeted therapies that block inflammatory pathways
activated in the context of anti-angiogenic treatment would be important to select candidate drugs …

… times of 54.4 months in selected patients. Despite improved … new drug targets, and stratification
strategies to better select … adjuvant treatment for pancreatic cancer, identifies evidence …